AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3038423 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice daily
Number of subjects: 7
Study 3038423 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 to 10 mg once daily
Number of subjects: 7
Study 3038423 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 7
Study 29457671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine and dronabinol
Number of subjects: 62
Study 27069153 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG instillation (one-third dose, three weekly instillations every 6 months for 3 years)
Number of subjects: 146
Study 27069153 — intervention group
Group type: COMPARATOR
Intervention: BCG instillation (two weekly instillations every 3 months for 3 years)
Number of subjects: 146
Study 27069153 — intervention group
Group type: EXPERIMENTAL
Intervention: NRAMP1 D543N polymorphism (allele A)
Number of subjects: 146
Study 27069153 — intervention group
Group type: EXPERIMENTAL
Intervention: NRAMP1 and hGPX1 gene polymorphisms
Number of subjects: 146
Study 27069153 — intervention group
Group type: EXPERIMENTAL
Intervention: NRAMP1 D543N GG genotype
Number of subjects: 146
Study 24699259 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 counts-per-minute (CPM) cut-point for hip placement
Number of subjects: 125
Study 24699259 — intervention group
Group type: EXPERIMENTAL
Intervention: Various cut-points (100 CPM, 200 CPM, 300 CPM, 500 CPM, 800 CPM, 1100 CPM) for wrist placement
Number of subjects: 125
Study 24699259 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC-derived cut-point for hip vector magnitude
Number of subjects: 125
Study 24699259 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC-derived cut-point for wrist vertical axis
Number of subjects: 125
Study 24699259 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC-derived cut-point for wrist vector magnitude
Number of subjects: 125
Study 23733528 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication diary-book
Number of subjects: 109
Study 23733528 — intervention group
Group type: COMPARATOR
Intervention: Control (standard parental education program and donated chemotherapy)
Number of subjects: 109
Study 20416246 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema administered before surgery
Number of subjects: 162
Study 20416246 — intervention group
Group type: COMPARATOR
Intervention: No enema administered (Control)
Number of subjects: 162
Study 17588820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 168
Study 17588820 — intervention group
Group type: COMPARATOR
Intervention: Kyphoplasty
Number of subjects: 168
Study 16548361 — intervention group
Group type: EXPERIMENTAL
Intervention: Guchong Zhixue Decoction (GCZXD) taken orally
Number of subjects: 60
Study 16548361 — intervention group
Group type: COMPARATOR
Intervention: Yigong Zhixue Oral Liquid, taken orally
Number of subjects: 60
Study 16548361 — intervention group
Group type: EXPERIMENTAL
Intervention: Guchong Zhixue Decoction (GCZXD)
Number of subjects: 60
Study 16548361 — intervention group
Group type: COMPARATOR
Intervention: Yigong Zhixue Oral Liquid
Number of subjects: 60
Study 12968087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 460
Study 12968087 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 460
Study 12968087 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 460
Study 11135333 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to appearance stereotyping and discrimination information
Number of subjects: 66
Study 11135333 — intervention group
Group type: COMPARATOR
Intervention: Control topic of television violence and aggression
Number of subjects: 66
Study 9778550 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI patients
Number of subjects: 18
Study 9778550 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 8157777 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 36
Study 8157777 — intervention group
Group type: COMPARATOR
Intervention: Vehicle paste (control group)
Number of subjects: 36
Study 2901815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow release morphine 30 mg
Number of subjects: 62
Study 2901815 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 30 mg
Number of subjects: 62
Study 28348380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetris-based intervention (trauma memory reminder cue plus approximately 20 minutes of game play)
Number of subjects: 0
Study 28348380 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control (written activity log for the same duration)
Number of subjects: 0
Study 28348380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetris-based intervention
Number of subjects: 0
Study 28348380 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 0
Study 28776345 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime solifenacin dosing
Number of subjects: 127
Study 28776345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime solifenacin dosing
Number of subjects: 127
Study 26196952 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 21
Study 23921652 — intervention group
Group type: COMPARATOR
Intervention: 3 mg epidural morphine
Number of subjects: 90
Study 23921652 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg epidural morphine
Number of subjects: 90
Study 20622407 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of lifestyle risk factors of noncommunicable diseases (NCDs)
Number of subjects: 375
Study 20622407 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of passive smoking, early age at marriage, and reuse of cooking oil as risk factors for NCDs
Number of subjects: 375
Study 18371466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher stent (Johnson & Johnson)
Number of subjects: 2260
Study 18371466 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision stent (Abbott Vascular)
Number of subjects: 2260
Study 18371466 — intervention group
Group type: EXPERIMENTAL
Intervention: Xience stent (Abbott Vascular)
Number of subjects: 2260
Study 18371466 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium bare-metal stents
Number of subjects: 2260
Study 18371466 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month dual antiplatelet therapy
Number of subjects: 2260
Study 17023236 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Setting Behavior Management (NSBM)
Number of subjects: 37
Study 17023236 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 37
Study 17023236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 14664687 — intervention group
Group type: EXPERIMENTAL
Intervention: Providers considered as fixed factors
Number of subjects: 0
Study 14664687 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical power in fixed model
Number of subjects: 0
Study 14664687 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects analysis
Number of subjects: 0
Study 10928769 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK (more than -5 D)
Number of subjects: 103
Study 10928769 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK (more than -5 D)
Number of subjects: 103
Study 10928769 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK (less than -5 D)
Number of subjects: 103
Study 10928769 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK (less than -5 D)
Number of subjects: 103
Study 8751803 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM (30 mg/day) and MPA (800 mg/day)
Number of subjects: 92
Study 8751803 — intervention group
Group type: COMPARATOR
Intervention: TAM (30 mg/day)
Number of subjects: 92
Study 8751803 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (800 mg/day)
Number of subjects: 92
Study 8751803 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 92
Study 1419204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective diary
Number of subjects: 598
Study 1419204 — intervention group
Group type: COMPARATOR
Intervention: Retrospective diary
Number of subjects: 598
Study 30452719 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (mainly UFT)
Number of subjects: 5006
Study 30452719 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (non-participation in trial)
Number of subjects: 5006
Study 28125330 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant practice (NDG; n=11)
Number of subjects: 30
Study 28125330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral practice (BG; n=8)
Number of subjects: 30
Study 28125330 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n=11)
Number of subjects: 30
Study 27100432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified infliximab regimen for 12 weeks
Number of subjects: 28
Study 27100432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmune PK failure
Number of subjects: 28
Study 27100432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmune PK failures after 12 weeks
Number of subjects: 28
Study 27100432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmune PK failures during IFX intensification
Number of subjects: 28
Study 24550184 — intervention group
Group type: EXPERIMENTAL
Intervention: Scorpion antivenom (SAV) plus prazosin
Number of subjects: 50
Study 24550184 — intervention group
Group type: COMPARATOR
Intervention: Prazosin alone
Number of subjects: 50
Study 22215277 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated detection of dual p16/Ki67 immunoreactivity
Number of subjects: 18068
Study 20730395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 301
Study 17574466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA) for measuring juxta-articular bone mineral density (BMD) at MCP joints
Number of subjects: 38
Study 17574466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA) for measuring whole hand (WH) BMD
Number of subjects: 38
Study 17574466 — intervention group
Group type: COMPARATOR
Intervention: Patients with rheumatoid arthritis criteria
Number of subjects: 38
Study 16236870 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea Risk Evaluation System (ARES)
Number of subjects: 299
Study 16236870 — intervention group
Group type: EXPERIMENTAL
Intervention: ARES (unattended at home)
Number of subjects: 299
Study 12229970 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Number of subjects: 10
Study 12229970 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 10
Study 10441825 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIF with Moss-Miami implants
Number of subjects: 12
Study 10441825 — intervention group
Group type: COMPARATOR
Intervention: PLIF with threaded cages (BAK-cages)
Number of subjects: 12
Study 7779349 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive early intervention
Number of subjects: 0
Study 7779349 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of home visits, days attended at child centers, number of parent meetings attended
Number of subjects: 0
Study 7779349 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2126002 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-drug combination chemotherapy (VMCP)
Number of subjects: 0
Study 2126002 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide-prednisolone (CP)
Number of subjects: 0
Study 6999239 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 14
Study 6999239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31823503 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention designed to augment the BFPC program
Number of subjects: 0
Study 31823503 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31093941 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist led medication review using the RASP list
Number of subjects: 61
Study 31093941 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 61
Study 31093941 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist interventions (across three controlled studies)
Number of subjects: 61
Study 27647465 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning training platform for continuous medical education
Number of subjects: 374
Study 25847778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 25847778 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 60
Study 24429785 — intervention group
Group type: EXPERIMENTAL
Intervention: Parodontocid mouthrinse used in conjunction with normal brushing and flossing
Number of subjects: 60
Study 24429785 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush and prophylactic toothpaste
Number of subjects: 60
Study 21957592 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetin
Number of subjects: 0
Study 21957592 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 21957592 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain syndrome therapy (Duloxetin and Gabapentin)
Number of subjects: 0
Study 19620930 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight + 0.125 g/kg carbohydrate)
Number of subjects: 17
Study 19620930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.125 g/kg carbohydrate)
Number of subjects: 17
Study 17225141 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg urapidil
Number of subjects: 12
Study 17225141 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin
Number of subjects: 12
Study 17225141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15072419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin
Number of subjects: 0
Study 15072419 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic buffer solution (placebo)
Number of subjects: 0
Study 11724460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with marine oil or single-cell oil sources of LC-PUFA
Number of subjects: 0
Study 11724460 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation
Number of subjects: 0
Study 11724460 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation
Number of subjects: 0
Study 9060016 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha‐adrenoreceptor antagonist)
Number of subjects: 0
Study 9060016 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 8484505 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg alfentanil (A15)
Number of subjects: 60
Study 8484505 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg alfentanil (A30)
Number of subjects: 60
Study 8484505 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 micrograms/kg alfentanil (A45)
Number of subjects: 60
Study 8484505 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 3625846 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine irrigation
Number of subjects: 100
Study 3625846 — intervention group
Group type: COMPARATOR
Intervention: Control (no chlorhexidine irrigation)
Number of subjects: 100
Study 29437574 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (apolipoprotein A-I [human])
Number of subjects: 0
Study 28145396 — intervention group
Group type: EXPERIMENTAL
Intervention: Actimove sling
Number of subjects: 28
Study 28145396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulderlift sling
Number of subjects: 28
Study 28145396 — intervention group
Group type: COMPARATOR
Intervention: No sling (control group)
Number of subjects: 28
Study 25933364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 97
Study 25933364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study 23819667 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized in-home nursing care plan
Number of subjects: 94
Study 23819667 — intervention group
Group type: COMPARATOR
Intervention: Standard care at mental health center
Number of subjects: 94
Study 21597232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure for 10 minutes on workday mornings
Number of subjects: 61
Study 21597232 — intervention group
Group type: COMPARATOR
Intervention: Non-BL periods
Number of subjects: 61
Study 17917935 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream, 8 weeks of treatment with once‐daily dosing for alternate weeks (R1)
Number of subjects: 32
Study 17917935 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream, 5 weeks of once‐daily dosing with a 1‐week interval (R2)
Number of subjects: 32
Study 17917935 — intervention group
Group type: COMPARATOR
Intervention: Composite median visual analogue scores at week 8
Number of subjects: 32
Study 17313005 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 95
Study 17313005 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (oral administration)
Number of subjects: 95
Study 15297112 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate treatment (12.5%, 800 + 400 ml, n = 8)
Number of subjects: 14
Study 15297112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 14
Study 10642712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass grafting surgery
Number of subjects: 526
Study 10642712 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 526
Study 10642712 — intervention group
Group type: COMPARATOR
Intervention: Medical management (unmatched patients)
Number of subjects: 526
Study 10642712 — intervention group
Group type: COMPARATOR
Intervention: Medical management (matched patients)
Number of subjects: 526
Study 9309461 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized approach to controlled ovarian hyperstimulation (COH) based on BMI and WHR
Number of subjects: 0
Study 9309461 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol for controlled ovarian hyperstimulation (COH)
Number of subjects: 0
Study 8157045 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 15
Study 8157045 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline slow-release 7.5 mg
Number of subjects: 15
Study 8157045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3565935 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 4
Study 3565935 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 4
Study 3565935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31657168 — intervention group
Group type: EXPERIMENTAL
Intervention: PGLA thread-embedding therapy combined with rehabilitation training
Number of subjects: 60
Study 31657168 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture combined with rehabilitation training
Number of subjects: 60
Study 28343601 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652 (1 of 5 doses)
Number of subjects: 248
Study 28343601 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652
Number of subjects: 248
Study 28343601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 26489661 — intervention group
Group type: EXPERIMENTAL
Intervention: specialised Helping Young People Early service model plus up to 16 sessions of individual cognitive analytic therapy
Number of subjects: 135
Study 26489661 — intervention group
Group type: COMPARATOR
Intervention: Helping Young People Early service plus up to 16 sessions of a control psychotherapy condition known as 'befriending'
Number of subjects: 135
Study 26489661 — intervention group
Group type: COMPARATOR
Intervention: a general youth mental health care model plus up to 16 sessions of befriending
Number of subjects: 135
Study 24188276 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive traditional Chinese medicine rehabilitation protocol
Number of subjects: 722
Study 24188276 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 722
Study 21347988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast presentation rates (auditory ISL)
Number of subjects: 0
Study 21347988 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow presentation rates (visual ISL)
Number of subjects: 0
Study 19422296 — intervention group
Group type: EXPERIMENTAL
Intervention: AdoMet (800 mg per day) for 4 weeks
Number of subjects: 52
Study 19422296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17174632 — intervention group
Group type: EXPERIMENTAL
Intervention: Opinion leader intervention (patient-specific one-page evidence summaries)
Number of subjects: 171
Study 17174632 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 171
Study 17174632 — intervention group
Group type: EXPERIMENTAL
Intervention: Opinion leader intervention (in HF subgroup)
Number of subjects: 171
Study 17174632 — intervention group
Group type: COMPARATOR
Intervention: Usual care (HF subgroup control)
Number of subjects: 171
Study 17174632 — intervention group
Group type: EXPERIMENTAL
Intervention: Opinion leader intervention (in IHD subgroup)
Number of subjects: 171
Study 17174632 — intervention group
Group type: COMPARATOR
Intervention: Usual care (IHD subgroup control)
Number of subjects: 171
Study 14977622 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 19
Study 14977622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11731184 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin and 1 alpha-hydroxycholecalciferol combination
Number of subjects: 202
Study 11731184 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin alone
Number of subjects: 202
Study 11731184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol alone
Number of subjects: 202
Study 11731184 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 202